Thu Oct 21 2021


suPAR is associated with risk for thromboembolic complications and mortality in patients with COVID-19


Higher suPAR levels at the time of hospital admission are associated with a higher risk for thromboembolic complications i.e., pulmonary embolism (PE) and deep venous thrombosis (DVT), as well as mortality in patients with COVID-19.

new study: suPAR and the risk for thromboembolic complications


Per quartile higher suPAR level, there was a higher risk for PE or DVT. Compared to those in the lowest suPAR quartile, patients in the highest quartile had an 11.1 times higher risk for PE/DVT. suPAR is also associated with overall mortality, with a 2.25 times higher risk of death seen per quartile increase in suPAR level.


This is a retrospective cohort study, conducted by Rush University Medical Center, of a random sample of 109 patients among those hospitalized between March and June 2020 for COVID-19, who had blood samples collected and stored on admission.

Patients were subsequently grouped by suPAR quartiles. Associations between suPAR, thromboembolic complications, and overall mortality were evaluated using multivariable logistic regression.


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates